A systematic review and meta-analysis of cerebrospinal fluid amyloid and tau levels identifies mild cognitive impairment patients progressing to alzheimer’s disease

HIGHLIGHTS

• who: Yunxing Ma and collaborators from the Studies measuring CSF levels of Au03b2(1-42) and/or tau (T-tau, and/or, tau) were includedIt was also necessary for the studies to include the values for these analytes at baseline (initial visit) and then at one or more subsequent time points for the healthy controls and the patients along with their diagnostic status (MCI, AD, or another form of dementia). To be included, the studies also needed to state which criteria were used for the diagnosis of MCI and AD. For CSF analyte levels, the study needed . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.